On September 26, 2025, Fractyl Health, Inc. announced significant interim results from its REMAIN-1 Midpoint Cohort study, showing that patients using the Revita DMR System lost an additional 2.5% body weight after discontinuing tirzepatide, while control patients regained 10%. The event represents a significant step in obesity treatment and builds confidence for ongoing clinical trials.